Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Compound CAR T – a double whammy with promise for AML

Publish date:: June 15, 2020

Key clinical point: Compound CAR T therapy against CLL1 and CD33 appears to be effective, with manageable toxicity.

Major finding: Seven of nine relapsing/refractory acute myeloid leukemia patients had no sign of residual disease 4 weeks afterward.

Study details: Open-label investigation in nine subjects

Disclosures: The work was funded by iCell Gene Therapeutics. Several investigators were employees. The researchers did not report any disclosures.

Citation:

Liu F et al. EHA Congress. Abstract S149.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,